Cooperative Agreement U01IP000480

Summary of Cooperative Agreement Award Vanderbilt University Medical Center (VUMC) received a $887,964 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 13, 2026, with completion targeted for March 31, 2031. The award supports a clinical research study investigating the immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccines...

The Board of Regents of the University of Nebraska received a $799,792 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with a completion date of March 31, 2031. The project focuses on developing a universal influenza vaccine designed to provide broad, long-lasting protection against divergent influenza virus strains. The research combines multiple vaccine...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $661,313 Project Grant (R01) to Massachusetts General Hospital effective February 6, 2026, through January 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research focuses on developing a universal influenza vaccine by eliciting pan-influenza A broadly neutralizing antibodies (BNAbs) through engineered nanoparticle immunogens. The investigation...

Federal Project Grant Award Summary Georgia TECH Research Corp received a $390,942 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 12, 2025, with a completion date of May 31, 2030. The project focuses on the research and development of self-assembled peptide nanoparticles (SAPNs) as a universal influenza vaccine platform. The research effort addresses the limitation...

Cooperative Agreement Summary Vanderbilt University received a $1.2 million Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 19, 2025, with completion targeted for April 30, 2030. This award supports the development of computational tools leveraging artificial intelligence and machine learning (AI/ML) to design broadly protective influenza vaccines. The research...

The American Samoa Department of Health received a Cooperative Agreement award of $761,812 from the Centers for Disease Control and Prevention (CDC) under the CDC Investigations and Technical Assistance program (CFDA 93.283), effective July 1, 2025, through June 30, 2030. The American Samoa Immunization Program (ASIP) will strengthen vaccine-preventable disease prevention and response through comprehensive immunization services designed to address persistent challenges of low vaccination...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Viva Viral Vaccines, Inc. a Project Grant totaling $299,968 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of September 25, 2025 through August 31, 2026. The award supports development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein to provide enhanced protection against seasonal and pandemic...

Federal Cooperative Agreement Summary Emory University received a $877,587 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 22, 2025, with completion targeted for July 31, 2030. The agreement funds a Phase 2B randomized open-label clinical trial to evaluate dengue immunity elicited by heterologous prime-boost vaccination combinations using TAK-003 and...

Federal Grant Award Summary The National Institutes of Health (NIH) Office of the Director awarded $286,793 to the Benaroya Research Institute at Virginia Mason on September 24, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to conduct clinical trial planning activities for a study evaluating high-dose influenza vaccine safety and efficacy in individuals with Down syndrome under age 65. This R34 planning grant supports preparation for a randomized-controlled clinical trial...

Federal Project Grant Award Summary Award Details: The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $676,666 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Massachusetts General Hospital, effective September 3, 2025 through August 31, 2030. The award supports research to develop an enhanced influenza messenger RNA (mRNA) vaccine utilizing a self-amplifying mRNA (saRNA) formulation delivered via microneedle patch technology....